PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Reminder: Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
-- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults
-- Provide an Update on the RSV F Vaccine Development Program

GAITHERSBURG, Md., July 21, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ETNovavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older).  In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults, as well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.

Preliminary webcast agenda:

  1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
  2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
  3. Update on the Prepare™ trial for Infants via Maternal Immunization

Conference call details are as follows:

Date:

Monday, July 24, 2017

Time:

4:30 p.m. U.S. Eastern Time (ET)

Dial-in number:

(877) 212-6076 (Domestic) or (707) 287-9331 (International)

Passcode:

54820069

Webcast:

www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates:

Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET, July 31, 2017 

Dial-in number:

(855) 859-2056 (Domestic) or (404) 537-3406 (International)

Passcode:

54820069

Webcast:

www.novavax.com, "Investors"/ "Events", until October 24, 2017

About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:    

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com 
maggie.beller@russopartnersllc.com 
212-845-4271  

View original content:http://www.prnewswire.com/news-releases/reminder-novavax-to-host-an-rsv-f-vaccine-update-conference-call-and-webcast-on-july-24-2017-at-430-pm-300492231.html

SOURCE Novavax, Inc.